Code Details & Principles for BT210
Code details & principles for
BT210
- Chapter 20 / Radiotherapy
- Chapter 6 / Thyroid and Parathyroid Glands
| Code | Description | Chapter/Sub-Chapter | Code Specific Guidance |
|---|---|---|---|
| BT210 | Oral introduction of liquid radioactive agent for malignant thyroid tumour ablation | 20.0.0 Radiotherapy, 6.9.0 Thyroid and Parathyroid Glands | Replaces BT200 Oral introduction of liquid radiopharmaceutical for thyroid tumour ablation (brachytherapy) |
Unacceptable Combinations for BT210
| CCSD Code (unacceptable combination) | Narrative (unacceptable combination) | Date Added |
|---|---|---|
| G4410 | Therapeutic oesophago-gastro-duodenoscopy (OGD) with insertion of prosthesis | 2014-08-06 |
| G4430 | Therapeutic oesophago-gastro-duodenoscopy (OGD) with dilatation | 2011-09-05 |
| G6500 | Diagnostic oesophago-gastro-duodenoscopy (OGD) includes forceps biopsy, biopsy urease test and dye spray | 2014-04-25 |
Coding Principles
These coding principles set out how the authors intend that the codes and narratives within the CCSD Schedule are interpreted and used. The outputs are available to be used by all individual insurers and providers including CCSD and non-CCSD members. Please note that:
- The CCSD Group does not discuss nor determine classifcations, reimbursement or fees - all insurers will have their own view on these matters
- The inclusion of a procedure code and/or its associated coding principles in the CCSD Schedule does not necessarily mean that it is endorsed by all members of the CCSD Group and codes may or may not be included in individual insurers' own Schedules or covered
- The coding principles are non-exhaustive guidelines only - each individual insurer may choose whether or not to adopt an individual combination of codes in practice and you will need to contact the insurer for further information